drugset / Trial / NCT01469039

A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

NCT01469039

Phase 3 Completed 623 enrolled Alkermes, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.

Timeline

Start
2011-12
Primary completion
2014-01
Completion
2014-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Lauroxil Small molecule 441 mg Intramuscular
Subject Aripiprazole Lauroxil Small molecule 882 mg Intramuscular

Indications